Helen Brew Gerlach - March 11, 2025 Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report We are delighted to release our latest report Innovations in antibody-drug conjugates and ...
Joanna Smith - October 2, 2024 Mewburn Ellis: top tier firm Legal 500 2025 We are extremely proud to once again be ranked tier one for our patent and trade mark practices in ...
Robert Andrews - August 20, 2024 Antibody-drug conjugates: the new frontier of cancer treatments Antibody-drug conjugates (ADCs) are big business. Big pharma is moving in, snapping up companies or ...
Robert Andrews - January 4, 2024 Podcast with Robert Andrews: a forward-thinking approach to inclusion & diversity Robert Andrews joins Lisa Mueller and Vivian Luiz Coco on their Inclusion Evolution podcast to ...
Joanna Smith - October 5, 2023 Mewburn Ellis: top tier firm Legal 500 2024 We are extremely proud to once again be ranked tier one for our patent and trade mark practices in ...
Robert Andrews - May 22, 2023 Podcast with Robert Andrews: how to drive I&D progress and engage key stakeholders Robert Andrews joins Natasha Rainey on her All Inclusive Podcast to discuss his journey to becoming ...
Frances Salisbury - February 10, 2023 Women and Girls in Science Day: Mewburn Ellis celebrates women in STEM fields Saturday 11 February 2023 marks the 8th International Women and Girls in Science Day.
Robert Andrews - October 20, 2022 Mewburn Ellis Partner with the General Counsel for Diversity & Inclusion We're Proud to Partner with the General Counsel for Diversity & Inclusion (GCD&I) GCD&I ...
Jacqueline Murphy - October 14, 2022 Mewburn Ellis: top tier firm Legal 500 2023 We are extremely proud to be ranked tier one for our patent and trade mark practices in the 2023 ...
Jacqueline Murphy - October 7, 2022 WIPR Diversity Champions & Trailblazers 2022 Congratulations to Robert Andrews and Rebecca Campbell on being recognised as a World Intellectual ...
Robert Andrews - August 3, 2022 So you want to be a STEMinist The gender imbalance in science and technology is startling. A bold group of pioneers is showing ...
Robert Andrews - June 28, 2022 Mewburn Ellis announces firmwide menopause policy We are delighted to have launched a firmwide menopause policy to encourage discussion around, and ...
Robert Andrews - May 4, 2022 How to be a leader on Inclusion & Diversity Mewburn Ellis is rethinking I&D from top to bottom. But what is the best strategy? New Chief ...
Maria Hall - April 26, 2022 Most 16–25-year-olds in Britain unsure of their intellectual property rights over their creations New research carried out by Mewburn Ellis in conjunction with YouGov to mark World Intellectual ...
Robert Andrews - March 28, 2022 ‘I blamed myself for my differences’: neurodivergence and IP During Neurodiversity Celebration Week 2022, former Mewburn Ellis Trade Mark Attorney Rebecca ...
Maria Hall - January 10, 2022 Mewburn Ellis appoints Chief Inclusion & Diversity Officer We are delighted to announce this new role alongside launch of Inclusion & Diversity ...
Robert Andrews - April 30, 2020 BerGenBio’s bemcentinib selected for fast track as potential treatment for coronavirus (COVID-19) In the fight against the coronavirus pandemic, bemcentinib produced by BerGenBio has been selected ...
